2025
Sex-specific effects of exogenous asparagine on colorectal tumor growth, 17β-estradiol levels, and aromatase
Aladelokun O, Benitez K, Wang Y, Jain A, Berardi D, Maroun G, Shen X, Roper J, Gibson J, Sumigray K, Khan S, Johnson C. Sex-specific effects of exogenous asparagine on colorectal tumor growth, 17β-estradiol levels, and aromatase. Pharmacological Research 2025, 107736. PMID: 40228761, DOI: 10.1016/j.phrs.2025.107736.Peer-Reviewed Original ResearchTumor-specific survivalColorectal cancerTumor growthR2G2 miceIncreased serum estradiol levelsSerum estradiol levelsSub-populations of macrophagesAssociated with cancer prognosisSuppressed tumor growthColorectal tumor growthExogenous asparagineColorectal cancer developmentColorectal cancer cellsNegative feed-back effectEstradiol levelsGlutamate levelsSex-related differencesSex-specific effectsMale miceCancer prognosisAsparagine supplementationCancer progressionMiceDecreased numberTumorHMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer
Gao Y, Fu S, Peng Y, Zhou Y, Zhu J, Zhang X, Cai C, Han Y, Shen H, Zeng S. HMBOX1 reverses autophagy mediated 5-fluorouracil resistance through promoting HACE1-induced ubiquitination and degradation of ATG5 in colorectal cancer. Autophagy 2025, ahead-of-print: 1-22. PMID: 40126194, DOI: 10.1080/15548627.2025.2477443.Peer-Reviewed Original ResearchColorectal cancer cellsColorectal cancerCancer cellsColorectal cancer tissuesColorectal cancer tissues of patientsLiquid chromatography-tandem mass spectrometryChromatography-tandem mass spectrometryFetal human colonProgression-free survivalClinical colorectal cancer tissuesFirst-line treatmentCell Counting Kit-8Cancer tissues of patientsPostoperative colorectal cancerCaspase 3Transmission electron microscopyCounting Kit-8Tissues of patientsMass spectrometryCleaved caspase 3Stable diseaseComplete responsePartial responseOverall survivalRegulation of chemoresistanceBenzene exposure and risk of colorectal cancer by anatomical subsite in the Norwegian offshore petroleum workers cohort
Babigumira R, Veierød M, Larsen I, Berge L, Shala N, Marjerrison N, Samuelsen S, Bråtveit M, Kirkeleit J, Nordby K, Hosgood H, Demers P, Vermeulen R, Kromhout H, Engel L, Nilsen T, Silverman D, Friesen M, Rothman N, Lan Q, Grimsrud T, Stenehjem J. Benzene exposure and risk of colorectal cancer by anatomical subsite in the Norwegian offshore petroleum workers cohort. Environmental Research 2025, 276: 121407. PMID: 40118315, DOI: 10.1016/j.envres.2025.121407.Peer-Reviewed Original ResearchRisk of colorectal cancerOffshore petroleum workersJob-exposure matrixHazard ratioColorectal cancerAnatomic subsiteColorectal cancer riskConfidence intervalsColorectal cancer casesEstimate hazard ratiosCase-cohort analysisPetroleum workersWork historyExposure-response associationsPositive exposure-response associationsBody mass indexRight-sided colon cancerPublic health implicationsPhysical activityBenzene exposureMeat intakeAlcohol intakeQuartile 4Mass indexCase cohortColorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
Gonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, Allende D, McHugh K, Shia J, Westerhoff M, Srivastava A, Chen W, Vazzano J, Swanson P, Chatterjee D, Cheema H, Ma C, Mannan R, Chetty R, Nowak K, Serra S, Agostini‐Vulaj D, Kazemimood R, Henn P, Kakar S, Choi W, Adeyi O, Jenkins S, Nagtegaal I. Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects. Histopathology 2025 PMID: 39887413, DOI: 10.1111/his.15412.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesAdenosquamous carcinomaColorectal adenosquamous carcinomaTumor buddingPoor prognosisMedian time to progressionMeta-analysis of cohortLow tumor buddingTime to progressionMale:female ratioReview of casesIndividual case seriesNodal metastasisRecurrent diseaseSquamous componentPatient ageRecurrence rateAcademic medical centreCase seriesImmunohistochemical featuresPrognostic aspectsClinicopathological analysisFemale ratioFollow-upColorectal cancerIdentifying metabolomic mediators of the physical activity and colorectal cancer relationship.
Papadimitriou N, Kazmi N, Tsilidis K, Richmond R, Lynch B, Bendinelli B, Ricceri F, Sánchez M, Trobajo-Sanmartín C, Jakszyn P, Simeon V, Severi G, Perduca V, Truong T, Ferrari P, Keski-Rahkonen P, Weiderpass E, Eichelmann F, Schulze M, Katzke V, Fortner R, Heath A, Aune D, Harewood R, Dahm C, Llorente A, Gunter M, Murphy N, Lewis S. Identifying metabolomic mediators of the physical activity and colorectal cancer relationship. Cancer Epidemiology Biomarkers & Prevention 2025, of1-of10. PMID: 39883068, DOI: 10.1158/1055-9965.epi-24-1390.Peer-Reviewed Original ResearchPhysical activityPA levelsReduced risk of colorectal cancerAssociated with CRC riskColorectal cancerRisk of colorectal cancerFalse discovery rate correctionColorectal cancer riskCancer prevention interventionsNested case-control studyMetabolomic signaturesCase-control studyCancer relationshipCRC riskBaseline questionnairePA measuresEPIC cohortPreventive interventionsInverse associationPA indexPhosphatidylcholine acyl-alkylReduced riskMediation analysisMetabolomics panelCirculating metabolomeDiverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis.
Zhao J, Ong J, Liu Y, Srivastava S, Teo M, Lee J, Walsh R, Loo L, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Sheng T, Lum J, Yong W, Pietrantonio F, Tan P, Sundar R. Diverse stromal phenotypes at spatial resolution in colorectal cancer peritoneal metastasis. Journal Of Clinical Oncology 2025, 43: 218-218. DOI: 10.1200/jco.2025.43.4_suppl.218.Peer-Reviewed Original ResearchCancer-associated fibroblastsT cell exhaustionPeritoneal metastasisT cellsStromal phenotypeColorectal cancerTissue microarrayStromal compartmentPoor prognosisSpatial distribution of T cellsColorectal cancer peritoneal metastasesIncreased CAFsClusters of T cellsCRC PMDistribution of T cellsTumor stroma compartmentAssociated with poor prognosisMemory B cellsDigital spatial profilingTranscoelomic disseminationTumor compartmentsStromal clustersPrognostic significanceTNF-alphaB cellsPredictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.
Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.Peer-Reviewed Original ResearchCRC-specific mortalityAll-cause mortalityCancer diagnosisColorectal cancerLong-term CRC survivorsNon-cancer related conditionsNon-metastatic colorectal cancerSEER-MedicareRisk of all-cause mortalityRecurrence of colorectal cancerColon cancerSEER-Medicare populationYear 5CRC survivorsSEER-Medicare databaseSurvivorship careRectal cancerFollow-up accountsColorectal cancer recurrenceMultiple co-morbiditiesMedicare claimsRetrospective cohort studyFine-Gray modelEstimate cumulative incidencePrimary risk factorIdentifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear follow-upPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrenceFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatmentCancer Mortality
Hjartåker A, Weiderpass E, Bray F. Cancer Mortality. 2025, 171-182. DOI: 10.1016/b978-0-323-99967-0.00162-9.Peer-Reviewed Original ResearchCancer mortality burdenMortality burdenCancer mortality trendsGlobal cancer controlCancer deathCancer mortality dataHigher-income settingsProportion of deathsMortality trendsMortality dataCause of cancer deathCancer controlColorectal cancerMiddle-income economiesMeasure of progressLiver cancerCancer formsMortality rateColorectalBurdenData sourcesWorld regionsCancerDeathFrequent cause
2024
Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis.
Zhang S, Kappil E, Zheng T, Boffetta P, Seyyedsalehi M. Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis. European Journal Of Cancer Prevention 2024 PMID: 39648934, DOI: 10.1097/cej.0000000000000935.Peer-Reviewed Original ResearchPFAS exposureStratified analysisMeta-analysisRisk of gastrointestinal cancerSystematic reviewGastrointestinal cancerModified Newcastle-Ottawa ScaleInternational Agency for Research on Cancer MonographsNewcastle-Ottawa ScaleSystematic review of literatureDose-response trendRandom-effects modelPancreatic cancerPotential confoundersIndependent reviewersYear of publicationPublication biasStudy designMeta-analysesColorectal cancerGastric cancerQuality scoresColorectalSubstance exposurePoly-fluoroalkyl substancesA Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer
Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz H, Kalyan A, Niedzwiecki D, Strickler J. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer. Journal Of Gastrointestinal Cancer 2024, 56: 29. PMID: 39652198, DOI: 10.1007/s12029-024-01156-x.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsMetastatic colorectal cancerPhase 2 studyEpidermal growth factor receptorAnti-tumor activityStable diseaseProgressive diseaseChemotherapy refractory metastatic colorectal cancerOral small-molecule tyrosine kinase inhibitorColorectal cancerResistance to epidermal growth factor receptorSmall molecule tyrosine kinase inhibitorsRefractory metastatic colorectal cancerBest overall responseRAS wild-typeAdvanced solid tumorsBiomarker-selected patientsTyrosine kinase inhibitorsWild-typeGrowth factor receptorResultsFive patientsPrimary endpointSecondary endpointsSolid tumorsSavolitinibMenopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
Macinnis R, Jenkins M, Milne R, John E, Daly M, Andrulis I, Colonna S, Phillips K, Investigators K, Le Marchand L, Newcomb P, Phipps A, Schmit S, Macrae F, Buchanan D, Gallinger S, Pai R, Samadder N, Giles G, Southey M, Hopper J, Terry M. Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk. JNCI Cancer Spectrum 2024, 9: pkae121. PMID: 39673461, PMCID: PMC11700558, DOI: 10.1093/jncics/pkae121.Peer-Reviewed Original ResearchFamily risk scoreMenopausal hormone therapyFamilial riskHazard ratioColorectal cancerFamilial risk of BCBreast cancerFamily historyDecreased colorectal cancerCancer family historyRisk of BCIncreased breast cancerAssociated with breastIncident BCNever usersGeneral populationRisk scoreHarmonized dataWomenHormone therapyRiskAssociationCancerNeverCohortPractice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer
Gupta P, Zhan P, Leeds I, Mongiu A, Reddy V, Pantel H. Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer. Journal Of Surgical Research 2024, 304: 371-382. PMID: 39615154, DOI: 10.1016/j.jss.2024.10.041.Peer-Reviewed Original ResearchLynch syndromePractice patternsCancers associated with Lynch syndromeColorectal cancerColon cancerNonmetastatic colorectal cancerDiagnosed CRC patientsMismatch repairDetect mismatch repairSurgical managementMMR-DMMR testingCRC patientsSurgical practice patternsAssociated with decreased ratesBlack raceRate of extended resectionDNA mismatch repairMismatch repair-proficient tumorsNational Cancer DatabaseNonmetastatic CRC patientsColon cancer patientsGermline mutationsCancer patientsTreatment decisionsAnalysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria.
Aderibigbe A, Dare A, Kalvin H, Olasehinde O, Wuraola F, Adisa A, Omisore A, Komolafe A, Omoyiola O, Okereke C, Katung A, Egberoungbe A, Ariyibi O, Olatoke S, Adeyeye A, Agodirin S, Bojuwoye M, Fayenuwo J, Ademakinwa O, Osinowo D, Lawal A, Abdulkareem F, Goldman D, Knapp G, Murthy S, Kahn R, Gonen M, Kingham T, Alatise O. Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria. Journal Of Surgical Oncology 2024 PMID: 39574208, DOI: 10.1002/jso.27878.Peer-Reviewed Original ResearchEmergency presentationsOverall survivalColorectal cancerCRC patientsCancer control effortsAssociated with worse OSCancer family historyElective patientsEmergency patientsRisk factorsLower household incomeLow educational levelOutcome of colorectal cancerProspective multicenter cohort studyStage IV diseaseSurgery improves survivalConsecutive CRC patientsKaplan-Meier methodLog-rank testMulticenter cohort studyAnalysis of risk factorsAccessing careProximal cancersMedian OSIV diseaseElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approachBalanced regulation of ROS production and inflammasome activation in preventing early development of colorectal cancer
Li L, Xu T, Qi X. Balanced regulation of ROS production and inflammasome activation in preventing early development of colorectal cancer. Immunological Reviews 2024, 329: e13417. PMID: 39523732, DOI: 10.1111/imr.13417.Peer-Reviewed Original ResearchRegulation of ROS productionBalanced ROS productionReactive oxygen speciesROS productionColitis-associated colorectal cancerInflammasome activationColorectal cancerInnate immune response to microbial infectionResponse to microbial infectionImmune response to microbial infectionReactive oxygen species sensorSource of ROS productionCell-cell contactNADPH oxidase complexInflammasome activation studiesReactive oxygen species generationASC speck formationBalance regulationCrohn's diseaseSignaling networksROS signalingSusceptibility genesNADPH complexPerinuclear regionSterile insults632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC)
Barbu A, Kothari P, Kahan S, Christenson E, Kazmi S, Manda S, Chisamore M, Kordahi S, Martz A, Nelson M, Morawski A, Flies D, Langermann S, Guha U, Myint H. 632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC). 2024, a727-a727. DOI: 10.1136/jitc-2024-sitc2024.0632.Peer-Reviewed Original ResearchUsing a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer
Siddique S, Baum L, Deziel N, Kelly J, Warren J, Ma X. Using a Bayesian analytic approach to identify county-level ecological factors associated with survival among individuals with early-onset colorectal cancer. PLOS ONE 2024, 19: e0311540. PMID: 39471191, PMCID: PMC11521299, DOI: 10.1371/journal.pone.0311540.Peer-Reviewed Original ResearchConceptsAge-of-onset colorectal cancerEarly-onset colorectal cancerEnd Results Program dataCenters for Disease Control and Prevention dataCounty-level factorsColorectal cancerHealth risk behaviorsIdentified principal componentsOdds of survivalPreventive servicesSurvival disparitiesLinear mixed modelsEOCRCChronic diseasesPreventive factorsUS countiesSalt Lake CountyCA residentsRisk behaviorsUnited StatesProgram dataCounty-levelOlder ageBayesian analytical approachYounger ageThe combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers
Lee J, Park H, Jin H, Jin L, Yoo S, Cho N, Bae J, Kim J, Kang G. The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. Journal Of Pathology And Translational Medicine 2024, 59: 50-59. PMID: 39440351, PMCID: PMC11736276, DOI: 10.4132/jptm.2024.09.26.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCaudal-type homeobox 2CD8 tumor-infiltrating lymphocytesTumor-infiltrating lymphocyte densitySurvival of patientsColorectal carcinomaStromal areaClinical outcomesHigh density of tumor-infiltrating lymphocytesDensity of tumor-infiltrating lymphocytesAdjuvant chemotherapy-treated patientsStage III colorectal carcinomaStage III colorectal cancerFOLFOX-treated patientsCancer-specific survivalChemotherapy-treated patientsIII colorectal carcinomaIII colorectal cancerTIL densityPrognostic factorsPrognostic parametersLymphocyte densityPrognostic markerCDX2 expressionColorectal cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply